Combined, Concurrent, and Sequential Administration of Seasonal Influenza and MF59-Adjuvanted A/H5N1 Vaccines: A Phase II Randomized, Controlled Trial of Immunogenicity and Safety in Healthy Adults

H5N1 Avian Influenza: Preventive and Therapeutic Strategies Against a Pandemic

(2010) Suryaprakash Sambhara et al.   Annual Review of Medicine

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

Vaccinate before the next pandemic?

(2010) Klaus Stöhr   NATURE

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

(2010) T. Vesikari et al.   PEDIATRICS

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

H5N1 influenza viruses: outbreaks and biological properties

(2009) Gabriele Neumann et al.   CELL RESEARCH

Progress with human H5N1 vaccines: a perspective from industry

(2009) Bram Palache et al.   Expert Review of Vaccines

Current status and progress of prepandemic and pandemic influenza vaccine development

(2009) Isabel Leroux-Roels et al.   Expert Review of Vaccines

Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

(2009) Luc Hessel et al.   Influenza and Other Respiratory Viruses

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects

(2009) R. Gasparini et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Heterosubtype Neutralizing Responses to Influenza A (H5N1) Viruses Are Mediated by Antibodies to Virus Haemagglutinin

(2009) Jean-Michel Garcia et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

(2009) Wendy Keitel et al.   VACCINE

Safety and immunogenicity of Sinovac’s prototype pandemic influenza H5N1 vaccines: a review on clinical trials

(2008) Yuan-Zheng Qiu et al.   Influenza and Other Respiratory Viruses

MF59® -adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

(2008) Angelika Banzhoff et al.   Influenza and Other Respiratory Viruses

Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

(2008) David I. Bernstein et al.   JOURNAL OF INFECTIOUS DISEASES

Human infection with highly pathogenic H5N1 influenza virus

(2008) Andrea Gambotto et al.   LANCET

Pathology of human influenza revisited

(2008) Thijs Kuiken et al.   VACCINE